Urine CXCL10 Chemokine Monitoring Post-renal Transplant

University Hospital Basel

Status: Completed

Conditions: Renal Transplant Rejection

Treatments: Drug: Rejection treatment according to clinical standard-of-care

Study type: Interventional

Funder types: Other

Identifiers

NCT03140514

Urine chemokine monitoring

Details and patient eligibility

About

In this study investigators will investigate whether early treatment of allograft rejection, as detected by urine CXCL10-monitoring, improves outcomes in renal allograft recipients.

Enrollment: 241 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• All consenting adult (age>=18) renal allograft recipients

Exclusion criteria

• Human Leucocyte Antigen (HLA) -identical living donor transplantation
• Primary non-function
• Participation in immunosuppression interventional trials

Trial design

Primary purpose: Diagnostic

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Single Blind

---

241 participants in 2 patient groups

Intervention

Experimental group

Description:

Urine CXCL10-chemokine levels will be monitored at specific time points post-transplant. Sustained elevated levels will trigger performance of a renal allograft biopsy. Any rejection will be treated. Rejection treatment according to clinical standard-of-care

Treatment:

Drug: Rejection treatment according to clinical standard-of-care

Control

No Intervention group

Description:

Urine CXCL10-chemokine levels will be monitored at specific time points post-transplant, but the values are concealed.